SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-23-000929
Filing Date
2023-01-05
Accepted
2023-01-04 17:43:13
Documents
1
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13D ea171252-13da2fsdevelop_disc.htm SC 13D/A 98126
  Complete submission text file 0001213900-23-000929.txt   100033
Mailing Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139
Business Address 300 ONE KENDALL SQUARE, 3RD FLOOR CAMBRIDGE MA 02139 (617) 401-4400
Disc Medicine, Inc. (Subject) CIK: 0001816736 (see all company filings)

IRS No.: 851613057 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91633 | Film No.: 23508391
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 NEW YORK NY 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 NEW YORK NY 94111 415 877 4887
FS Development Holdings, LLC (Filed by) CIK: 0001820810 (see all company filings)

IRS No.: 851613057
Type: SC 13D/A